Acceleron Pharma (NASDAQ:XLRN) announces positive results from a Phase 2 clinical trial, PULSAR, evaluating sotatercept in patients with pulmonary arterial hypertension (PAH).
The study met the primary endpoint of a
statistically significant reduction in pulmonary vascular resistance
(PVR) at week 24 versus placebo. Key secondary endpoints were also met.
Detailed data will be presented at a future medical conference.
Management will host a conference call today at 5:00 pm ET to discuss the results.
https://seekingalpha.com/news/3534880-accelerons-sotatercept-successful-in-pah-study-shares-up-55-after-hours
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.